Maze Therapeutics IPOs at $487M, targeting APOL1 Kidney Disease with MZE829 in Phase 2. Click here to read an analysis of MAZE stock now.

In a major step geared towards financial expansion, Meesho is actively working on an ambitious initial public offering (IPO), meant to raise $1 billion, according to the sources.Strategic Financial ...

Retail trading platform eToro filed to go public in the U.S., disclosing that its commissions surged last year amid rising ...

The IPO market began to show signs of life last year, and that momentum is expected to carry over into 2025. According to ...

As we settle into a new year, the global initial public offering landscape presents a fascinating tapestry of challenges and ...

New Zealand based Fonterra group said it was exploring an initial public offer in addition to a sell-off of international ...

ECONOMYNEXT - Fitch Ratings has affirmed '; the outlook is stable. Fitch Ratings has affirmed Citibank - Colombo Branch's national long-term rating at 'AAA(lka)'; the outlook is stable.

The IPO pipeline, according to Friedman, remains strong, with many companies ready to enter the public markets. However, the prevailing uncertainty—stemming from monetary policy changes, inflation ...

Getting an IPO’s pricing right in volatile markets is crucial—but not at the cost of investor quality. That’s the message Rahul Saraf, Head of Investment Banking at Citi, drove home at the ...

The design tech company is exploring a public offering after regulators stymied its $20 billion sale to the software giant Adobe in 2023.

Pres­i­dent Don­ald Trump’s nom­i­nees for NIH di­rec­tor and FDA com­mis­sion­er sailed through their re­spec­tive con­fir­ma­tion hear­ings this week, fac­ing few dif­fi­cul ...